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OBJECTIVES The purpose of this study was to determine whether QRS duration or morphology increased
the risk of adverse outcome in the DAVID (Dual Chamber and VVI Implantable
Defibrillator) trial.
BACKGROUND The DAVID trial found an increased risk of the combined end point of death and new or
worsening congestive heart failure (CHF) in defibrillator recipients who were paced
DDDR-70 versus VVI-40.
METHODS We analyzed the combined end point in patients with abnormal QRS duration (AbQRS)
(110 ms) compared with those with normal QRS duration (NQRS) (110 ms).
RESULTS The QRS data were available for 496 of the 506 patients enrolled in the trial, including
223 patients with NQRS (45%) and 273 patients with AbQRS (55%). In patients in
whom defibrillators were programmed to pace infrequently (VVI-40), having an NQRS
or AbQRS was not an indicator of increased risk of adverse outcome. However, among
patients in whom defibrillators were programmed in a manner that promoted more
frequent ventricular pacing (DDDR-70), there was a significant adverse interaction with
AbQRS; this combination was independently associated with a higher risk for developing
CHF or death (p  0.017).
CONCLUSIONS Although patients with AbQRS tended to have other risk factors associated with poor
outcome, the interaction of QRS duration with ventricular pacing (DDDR-70) indepen-
dently contributed to a worse outcome and therefore, was a marker of patients in whom such
treatment may be harmful. This should not imply that right ventricular pacing in NQRS
patients is safe but rather that pacing in the context of an AbQRS is probably best
avoided. (J Am Coll Cardiol 2006;48:1628–33) © 2006 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.05.071Cardiology Foundation
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there is a growing body of evidence that the dyssynchrony
nduced by right ventricular pacing has an adverse effect on
utcome in patients undergoing implantation of either a
ermanent pacemaker or an implantable cardioverter-
efibrillator (ICD) (1,2). The DAVID (Dual Chamber and
VI Implantable Defibrillator) trial found an increased risk
f the combined end point of death and hospitalization for
ew or worsening congestive heart failure (CHF) in ICD
atients paced DDDR-70 versus VVI-40. It is not clear
hat factors influence this adverse effect. Prolonged QRS
uration, an indicator of ventricular dyssynchrony, is a
redictor of adverse outcome in patients with CHF (3). We
ought to determine whether QRS duration or morphology
as an indicator of increased risk of adverse outcome in the
AVID trial.
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Regional Cardiology Associates, Sacramento, California; ‡Maine Medical Center,
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oordinators is published in reference 4 (JAMA 2002;288:3115–23).3
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e performed a subgroup analysis on DAVID trial patients
omparing outcome in those with abnormal QRS duration
AbQRS) (110 ms) with those with normal QRS duration
NQRS) (110 ms). Outcome was also compared between
hose with right bundle branch block (RBBB), left bundle
ranch block (LBBB), nonspecific intraventricular conduc-
ion delay (IVCD), and normal QRS duration (NQRS).
The DAVID trial was a multicenter, randomized, single-
linded, parallel-arm study of patients with ICDs, compar-
ng VVI and DDDR pacing modes. The methods and
esults have been previously reported (4). The DAVID
atients had a standard indication for an ICD but no
ndication for antibradycardia pacing. Transvenous dual-
hamber ICDs were implanted in all trial participants. After
uccessful implantation, patients were randomly assigned to
ave the device programmed to pace infrequently (VVI
ode with a lower rate of 40/min [VVI-40]) or in a manner
hat promoted ventricular pacing (DDDR mode with a
ower rate of 70/min [DDDR-70]). Programming of the
trioventricular interval was left to the clinical judgment of
he investigator, but was most commonly set at 180 ms. Atmonths’ follow-up, the pacing registry of implanted
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October 17, 2006:1628–33 Wide QRS in the DAVID Trialevices indicated that patients in the DDDR-70 group were
entricular paced 58% of the time compared with 2.4% in
he VVI-40 group. Patients were followed for 9.2  6
mean  SD) months.
efinitions. The QRS duration was reported as the aver-
ge of at least 3 measured QRS complexes on the pre-
mplant 12-lead electrocardiogram. An NQRS was defined
s 110 ms and AbQRS as 110 ms, based on generally
ccepted normal values for precordial QRS dimensions (5).
onspecific IVCD was defined as a QRS duration between
10 and 119 ms, or 120 ms in the absence of a typical
undle branch block pattern. Left bundle branch block was
efined as a QRS duration 120 ms with a wide notched
-wave in the left precordial leads (V4 through V6) and lead
, or with a pattern of rR= in the same leads. Right bundle
ranch block was defined as QRS duration 120 ms with
n rsR= complex in right precordial lead V1, a terminal R in
VR, and a terminal S in lead I.
nd points. The primary end point was a combined
reedom from death and absence of hospitalization for heart
ailure. The determination of heart failure hospitalization
as based on review of the hospital records by an events
ommittee that was blinded to treatment group. Hospital-
zation had to satisfy both of the following criteria: 1)
dmission to hospital for more than 24 h with a clinical
istory of worsening symptoms of heart failure as evidenced
y clinical criteria, including increased New York Heart
ssociation functional class, orthopnea, paroxysmal noctur-
al dyspnea, edema, dyspnea on exertion, or gastrointestinal
ymptoms attributable to heart failure; and 2) 1 or more
ntensive treatments for CHF within 24 h of admission,
uch as intravenous diuretics, intravenous inotropic medi-
ations, or placement on the status 1 heart transplant list.
ollow-up occurred every 3 months.
tatistics. Differences in continuous and dichotomous
ariables were analyzed with use of the Student t test, the
hi-square test, or the Mann-Whitney test. Event rates were
stimated by the product-limit method (SPSS version 10;
PSS Inc., Chicago, Illinois). Time to primary end point
as analyzed using the Kaplan-Meier method. Cox stepwise
egression was used to analyze the interaction of QRS group
nd pacing mode on the primary end point, while account-
Abbreviations and Acronyms
AbQRS  abnormal QRS
CHF  congestive heart failure
DAVID  Dual Chamber and VVI Implantable
Defibrillator
ICD  implantable cardioverter-defibrillator
IVCD  intraventricular conduction delay
LBBB  left bundle branch block
MOST  Mode Selection Trial
NQRS  normal QRS
RBBB  right bundle branch blockng for the main effects of baseline covariates, particularly ghose that differed substantially between the QRS groups.
election of the appropriate multivariate model was con-
rmed by the goodness-of-fit chi-square (Hosmer-
emeshow) test. Statistical significance was indicated by p
0.05.
ESULTS
atients. Data on QRS duration and morphology were
vailable for 496 of the 506 patients enrolled in the trial.
here were 223 patients with NQRS (45%), which averaged
5  10 ms, and 273 patients with AbQRS (55%), which
veraged 138  22 ms. Of the 273 patients with AbQRS,
2 (19%) had RBBB, 82 (30%) had LBBB, and 139 (51%)
ad IVCD morphology. Table 1 shows the clinical and
aboratory characteristics and medications of patients with
ormal and abnormal conduction. Patients manifesting
bnormal conduction were older, had a lower ejection
raction, were more likely to have a history of heart failure,
nd less likely to have hyperlipidemia, a percutaneous
oronary intervention, or coronary revascularization after
rial entry than patients with normal conduction. At hos-
ital discharge after receipt of the ICD, use of amioda-
one tended to be higher, and use of other antiarrhythmic
gents lower in patients with abnormal conduction, but
hese differences were not statistically significant. Nota-
ly, patients with abnormal QRS conduction also had a
onger PR interval at baseline, and had a narrower
ifference between the programmed atrioventricular delay
ssociated with atrial pacing and that associated with
trial sensing. At 3 months’ follow-up, the frequency of
entricular pacing was higher in patients with AbQRS
han in those with NQRS (33  41% vs. 25  36%
mean  SD]), respectively; p  0.03).
ffect of ventricular pacing assignment and QRS con-
uction on outcome. The rate of survival free of hospital-
zation for new or worsening heart failure was compared
etween patients with normal and abnormal QRS conduc-
ion in whom defibrillators had been programmed to pro-
ote (DDDR-70) or not promote (VVI-40) ventricular
acing. There was no difference in this measure of outcome
mong patients with NQRS, whether they were assigned to
e more frequently ventricular paced (DDDR-70) or infre-
uently paced (VVI-40) (Fig. 1) (p  0.94). Nor were there
ignificant differences in outcome among patients with
QRS or AbQRS if assigned to infrequent pacing (VVI-
0) (Fig. 2) (p  0.59). Conversely, those with an AbQRS
n whom ventricular pacing was promoted (DDDR-70) had
worse outcome than patients in whom it was not (VVI-40)
Fig. 3) (p  0.01). Figure 4 depicts outcome for the 3
ubgroups of patients with AbQRS—those with IVCD,
BBB, or LBBB. Differences in outcome between these 3
ubgroups were qualitatively similar, although only those
ith LBBB achieved a statistically significant difference in
he primary end point between DDDR-70 and VVI-40
roups. That is, patients with LBBB in whom ventricular
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Wide QRS in the DAVID Trial October 17, 2006:1628–33acing was promoted (DDDR-70) appeared to have a
igher likelihood of death or heart failure than those in
hom it was not (VVI-40) (p  0.03), although there was
visually apparent divergence in the survival curves for all 3
bQRS subgroups.
djusted outcomes. Cox regression analysis was per-
ormed, adjusting the primary outcome for differences in
aseline variables, including age, ejection fraction, revascu-
arization, history of heart failure, history of diabetes, serum
reatinine, PR interval, and use of nitrates, followed, in
urn, by QRS duration, promoted ventricular pacing
DDDR-70), and the interaction between QRS duration
able 1. Clinical and Laboratory Characteristics of Patients With
umber of patients, n (%)
ge at randomization, yrs (mean  SD)
jection fraction (mean  SD)
istory of MI, n (%)
istory of heart failure, n (%)
istory of atrial fibrillation or flutter, n (%)
istory of diabetes, n (%)
rior VF, n (%)
rior VT, n (%)
istory of unexplained syncope, n (%)
istory of hypertension, n (%)
istory of hyperlipidemia, n (%)
schemic cardiomyopathy, n (%)
ype of index arrhythmia
VF, n (%)
Syncopal VT, n (%)
Symptomatic VT, n (%)
Syncope with inducible VT or VF, n (%)
Hemodynamically stable VT, n (%)
Symptomatic NSVT with inducible VT or VF, n (%)
Asymptomatic NSVT with inducible VT or VF, n (%)
evascularization history
History of coronary revascularization surgery or percutaneous coronary
prior to index arrhythmia, n (%)
Coronary revascularization surgery or percutaneous coronary interventio
Any revascularization, n (%)
aboratory findings
Blood urea nitrogen, mg/dl (mean  SD)
Serum creatinine, mg/dl (mean  SD)
lectrocardiographic and pacing characteristics
Heart rate, beats/min (mean  SD)
PR interval, msec (mean  SD)
PR not measurable (AF or paced VVI), n (%)
QRS duration, msec (mean  SD)
Final: pacing AV delay, msec (mean  SD)
AV delay  PR interval (mean  SD)
edication usage at baseline hospital discharge
Nitrates, n (%)
Any antiarrhythmic medications, n (%)
Amiodarone, n (%)
Amiodarone total daily dose, mg (mean  SD)
Sotalol, n (%)
Other antiarrhythmic medications, n (%)
Antidepressant, n (%)
I  myocardial infarction; NSVT  nonsustained ventricular tachycardia; VF nd ventricular pacing (DDDR-70), as depicted in Table 2. ihe regression analysis identified a significant effect upon
utcome stemming from the combination of an AbQRS,
entricular pacing (DDDR-70), and the interaction be-
ween AbQRS and pacing corresponding to that seen in
igures 3 and 4 (p  0.017). That is, the adverse effects on
he primary outcome when ventricular pacing was promoted
DDDR-70) were much more pronounced in the AbQRS
han in the NQRS group. When not adjusted for baseline
ariables, there was only a trend toward an interaction
etween QRS duration and treatment upon the primary
utcome (p  0.13), probably owing to imbalances in other
redictive characteristics between groups. There was an
mal and Abnormal Conduction
QRS Duration
p Value>110 ms <110 ms
273 (55%) 223 (45%)
66  10 63  12 0.004
26  8 29  7 0.001
187 (69%) 150 (68%) 0.78
171 (63%) 108 (49%) 0.002
44 (16%) 24 (11%) 0.09
87 (32%) 71 (32%) 1.00
7 (3%) 11 (5%) 0.16
40 (15%) 24 (11%) 0.20
37 (14%) 30 (14%) 0.98
169 (62%) 144 (65%) 0.53
145 (53%) 141 (64%) 0.02
226 (83%) 189 (85%) 0.54
0.89
53 (19%) 38 (17%)
17 (6%) 15 (7%)
58 (21%) 39 (17%)
42 (15%) 37 (17%)
24 (9%) 21 (9%)
20 (7%) 16 (7%)
59 (22%) 57 (26%)
ention 156 (57%) 124 (56%) 0.74
r index arrhythmia, n (%) 32 (12%) 43 (19%) 0.02
171 (63%) 147 (66%) 0.44
24  11 22  11 0.03
1.3  1 1.4  2 0.80
71  15 73  15 0.17
191  40 174  34 0.001
5 (2%) 0 (0%) 0.07
138  22 95  10 0.001
201  30 206  36 0.31
7  53 32  46 0.001
72 (27%) 56 (26%) 0.78
94 (35%) 63 (29%) 0.15
87 (32%) 53 (24%) 0.05
364  242 426  248 0.15
6 (2%) 6 (3%) 0.71
2 (1%) 6 (3%) 0.15
34 (13%) 26 (12%) 0.81
ular fibrillation; VT  ventricular tachycardia.Nor
interv
n aftensufficient number of cases to distinguish whether this
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October 17, 2006:1628–33 Wide QRS in the DAVID Trialdverse effect was independently predicted by the specific
onduction abnormality (LBBB, RBBB, or nonspecific
VCD), as was suggested by the Kaplan-Meier survival
nalysis. For example, despite the apparent relationship
etween LBBB and treatment on outcome observed in
he univariate analysis, the interaction between the two,
ither unadjusted or adjusted for baseline variables, was
ot statistically significant (p  0.45 and 0.42, respec-
ively). This may have been because no such interaction
ruly existed or because the analysis was underpowered.
inally, in support of our prospective selection of a
onventional cut point of 110 ms to define abnormal
RS duration, when the regression analysis was re-
tricted to patients who already manifested such abnor-
al conduction, further increments in QRS duration
igure 1. Kaplan-Meier curve depicting the primary end point of death
r first hospitalization for new or worsening heart failure in patients
ith normal conduction who were programmed in a manner that did
DDDR-70) or did not (VVI-40) promote ventricular pacing. p  0.94.
igure 2. Kaplan-Meier curve depicting the primary end point of death or
rst hospitalization for new or worsening heart failure in patients with
ormal QRS (110 ms) (NQRS) or abnormal QRS (110 ms) (AbQRS)r
onduction who were programmed to pace infrequently (VVI-40) (p 
.59).ere not in themselves found to be a significant predictor
f the primary end point (p  0.89).
ISCUSSION
cross the spectrum from narrow to markedly prolonged,
RS duration has been shown to be an independent
arker of mortality in patients with and without conges-
ive heart failure (1,3,6). Recent studies have also ob-
erved that, when combined with severe left ventricular
ysfunction, right ventricular pacing worsens clinical
utcome (4,7), particularly when it occurs frequently (8).
n addition, multiple studies have shown the benefits of
iventricular pacing in patients with prolonged QRS
uration and CHF suggesting that a widened QRS is not
ust a marker of disease severity, but a possible indicator
f a treatable functional impairment (9,10). Taken to-
ether, these observations support the existence of an
dverse and potentially modifiable interaction between
eart failure, QRS duration, and pacing that was ad-
ressed by the present study.
When ventricular pacing was promoted (DDDR-70)
mong patients with impaired heart function, we found that
hose with a prolonged QRS duration (110 ms) had a
igher risk of death or new or worsening congestive heart
ailure compared with patients with a baseline narrow QRS
110 ms). When ventricular pacing was not promoted
VVI-40), having a normal or an abnormal QRS duration
as not an indicator of increased risk of adverse outcome.
or, apart from pacing considerations, was increasing
RS duration found to independently predict an adverse
utcome among patients in whom QRS was already
rolonged at baseline (110 ms). However, in combina-
ion with assignment to more frequent ventricular pacing
DDDR-70), a prolonged QRS was independently asso-
iated with a higher risk of an adverse outcome. These
igure 3. Kaplan-Meier curve depicting the primary end point of death
r first hospitalization for new or worsening heart failure in patients
ith abnormal conduction who were programmed in a manner that did
DDDR-70) or did not (VVI-40) promote ventricular pacing. p  0.01.esults suggest that patients with some degree of baseline
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Wide QRS in the DAVID Trial October 17, 2006:1628–33yssynchrony may be more susceptible to the adverse
ffects of further dyssynchrony induced by right ventric-
igure 4. Kaplan-Meier curve depicting the primary end point of death or
rst hospitalization for new or worsening heart failure in patients with
bnormal conduction due to right bundle branch block (RBBB) (A), a
onspecific conduction abnormality (IVCD) (B), or left bundle branch
lock (LBBB) (C) who were programmed in a manner that did (DDDR-
0) or did not (VVI-40) promote ventricular pacing. Statistical significance
or an adverse outcome associated with ventricular pacing (DDDR-70) was
bserved only in patients with LBBB (p  0.03).lar pacing. Although patients with a wide QRS tended Mo have other risk factors associated with poor outcome
such as increasing age, worse ejection fraction, and
igher likelihood of prior congestive heart failure), the
dverse interaction of QRS duration with assignment to
ore frequent ventricular pacing (DDDR-70) contrib-
ted to a worse outcome independent of these other risk
actors and, as such, was a marker of patients in whom
uch treatment should be avoided.
acing in bundle branch block. Although it could not be
stablished as an independent predictor, the adverse out-
ome in patients with increased QRS duration in whom
entricular pacing was promoted (DDDR-70) appeared to
e more strongly associated with LBBB than with RBBB or
onspecific IVCD. This observation is consistent with the
nown mechanical and hemodynamic consequences of
BBB on left ventricular function, which is simulated, and
rguably might even be exaggerated, by right ventricular
acing (11). However, nonsignificant trends toward worse
utcome in patients with RBBB and IVCD when paced
lso were observed which were qualitatively similar to those
ith LBBB. It is possible that ventricular pacing is
etrimental in the presence of an underlying conduction
isorder in any of its forms, and this trial was simply
nderpowered to establish these differences. It is also
ossible that the subgroup of patients with IVCD, which
ncluded those with more minor degrees of QRS prolon-
ation, might be expected to behave more like patients
ith NQRS and have less detrimental effects from
entricular pacing. Similarly patients with RBBB (in
hom the benefit from resynchronization therapy is less
ertain (12) may, by the same token, sustain less harm
rom the change in ventricular activation sequence caused
y right ventricular pacing.
acing in patients with a normal QRS. In our study we
ound no difference in the primary end point among patients
ith a normal QRS in whom ventricular pacing was
DDDR-70) or was not (VVI-40) promoted. This should
ot necessarily be taken to indicate there are no adverse
ffects from right ventricular pacing in patients with a
arrow baseline QRS. A subgroup analysis of the MOST
Mode Selection Trial) pacing trial showed an increased risk
f development of CHF and atrial fibrillation in patients
ith a “normal” QRS who received ventricular pacing (13).
ne explanation for this apparent discrepancy between
OST and DAVID lies in their selection of a wider QRS
120 ms) to define normal than the more conventional
efinition (110 ms) used in our trial. In the context of a
ider than normal QRS, both trials could be said to have
bserved ventricular pacing to be detrimental, whereas
his may or may not have been the case when the QRS
as truly narrow. Another explanation for this discrep-
ncy is the difference in the frequency of ventricular
acing between the 2 studies. The DDDR group in
OST was 90% ventricular paced compared with 58%
aced in DAVID. The VVI group was 58% paced in
OST compared with 2.4% in DAVID. These differ-
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October 17, 2006:1628–33 Wide QRS in the DAVID Trialnces stem from the different programming parameters as
ell as the fact that MOST patients had a primary
ndication for antibradycardia pacing. The MOST sub-
tudy observed an increasing risk of adverse outcomes
ssociated with the frequency of ventricular pacing. It is
herefore possible that patients in DAVID with a narrow
RS complex would have had a higher event rate had
heir frequency of ventricular pacing been greater or their
uration of follow-up been longer.
tudy limitations. This study is limited by the post-hoc
ature of the analysis. The DAVID trial was not primarily
esigned to study the effects of QRS duration on outcome
r in relation to ventricular pacing. The results do suggest,
owever, that patients with baseline electrocardiographic
vidence of dyssynchrony may be particularly prone to the
dverse effects of right ventricular pacing. Increased atten-
ion to programming and novel pacing modes are needed to
void right ventricular stimulation where possible. Prospec-
ive studies are required to define better alternatives, such as
iventricular pacing, for broader groups of patients who
equire ventricular pacing.
eprint requests: DAVID Clinical Trial Center, 1107 NE
5th St., Suite 505, Seattle, Washington 98105. E-mail:
avidctc@u.washington.edu. Correspondence: Dr. John J.
ayes, Department of Cardiology, Marshfield Clinic, 1000 N.
ak Avenue, Marshfield, Wisconsin 54449. E-mail: hayes.john@
arshfieldclinic.org.
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